Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Revenue

Other segment segments

Energy
$1.98B+19.5%
Automotive
$328M-5.7%
Investment
-$269M+19.0%
Food Packaging
$88M-8.3%
Home Fashion
$39M-2.5%
Holding Company
$5M-70.6%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%
Enterprise value$10.54B+5.3%
P/S0.5×0.0×

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — revenue?
Icahn Enterprises (IEP) reported pharma — revenue of $16M in Q1 2026.
How has Icahn Enterprises's pharma — revenue changed year-over-year?
Icahn Enterprises's pharma — revenue decreased by 33.3% year-over-year, from $24M to $16M.
What is the long-term trend for Icahn Enterprises's pharma — revenue?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — revenue has grown at a 5.4% compound annual growth rate (CAGR), from $85M to $105M.
What does pharma — revenue mean?
The aggregate top-line income for the pharmaceutical segment, combining net product sales and other operating revenues. This figure represents the total inflow of economic benefits from all segment-related business activities.